Table 1:
Author yr, ref | Study participation1 | Study attrition2 | Prognostic Factor Measurement3 | Outcome measurement3 | Statistical Analysis and Reporting4 | Overall risk of bias |
---|---|---|---|---|---|---|
(Bartsch et al., 2005) | + | + | − | − | − | High |
(Cejas et al., 2019) | + | ? | + | − | + | Moderate |
(Conemans et al., 2018a) DNA methylation profiling | + | ? | + | + | + | Low |
(Conemans et al., 2018b) p27Kip1 and p18Ink4c | + | ? | + | + | − | Moderate |
(Conemans et al., 2017a) WHO grade | + | ? | + | + | + | Low |
(Davi et al., 2011) | + | + | − | + | + | Moderate |
(D’Souza S et al., 2014) | − | ? | + | + | + | Moderate |
(Nell et al., 2018) | + | ? | + | + | + | Low |
(Partelli et al., 2016) | + | ? | + | Distant metastases: + Progression-free survival: − |
+ | Moderate |
(Pieterman et al., 2017) | + | + | + | + | + | Low |
(Sakurai et al., 2007) | + | ? | − | − | − | High |
(Triponez et al., 2006b) is surgery beneficial ≤ 2cm | + | − | + | − | + | High |
(Triponez et al., 2006a) Epidemiology data on 108 MEN1 NF-pNET | + | ? | Tumor size - Surgery + | − | + | High |
Symbols: + low risk of bias; − high risk of bias; ? unclear
In study participation, we judged the percentage of the population with MEN1-related NF-pNETs, whether the study population truly represents MEN1 patients as diagnosed according to the guidelines, the sample frame and recruitment, description of source population, and baseline characteristics.
Study attrition assessed loss to follow-up and whether this could have biased the relationship between prognostic factor and outcome.
For prognostic factor and outcome measurement, we assessed whether the measurement was clearly described, if the measurement was valid (according to predefined criteria), and whether the measurement was performed according to the same procedure in all participants.
For statistical analysis, we assessed whether this was adequately described, appropriate, and if there was no selective reporting. See also Supplemental Material 2.